Pfizer looks to have created some distance from its post earnings volatility, established succeeding higher-highs, backed by corporate news of new Operating Chief, and looks like could sustain a positive trend to close out 2017.
The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.